5-(4-chlorophenyl)-2-methylpyridine | 23148-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(4-chlorophenyl)-2-methylpyridine
• 英文别名: 5-(4-chloro-phenyl)-2-methyl-pyridine；2-methyl-5-(4-trifluoromethyl-phenyl)pyridine；5-(4-chlorophenyl)-2-picoline；5-(p-Chlorphenyl)-2-methylpyridin；5-(p-Chlorphenyl)-2-picolin
• CAS: 23148-35-8
• 化学式: C₁₂H₁₀ClN
• 分子量: 203.671
• InChiKey: HCGSTFDDYVKRJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-(4-chlorophenyl)-2-methylpyridine 生成 5-(4-chlorophenyl)-2-picolyl chloride
  参考文献：
  名称：

  Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene

  摘要：

  具有I式化合物的化合物：##STR1##是5-脂氧合酶的抑制剂和白细胞三烯生物合成的抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还有助于治疗心绞痛、脑血管痉挛、肾小球肾炎、肝炎、内毒素血症、银屑病、葡萄膜炎和异体移植排斥，并预防动脉粥样硬化斑块的形成。

  公开号：

  US05314900A1
• 作为产物：
  描述：

  5-溴-2-甲基吡啶 、 4-氯苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 水 、 甲苯 为溶剂， 生成 5-(4-chlorophenyl)-2-methylpyridine
  参考文献：
  名称：

  Inhibition of 1-Deoxy-d-Xylulose-5-Phosphate Reductoisomerase by Lipophilic Phosphonates: SAR, QSAR, and Crystallographic Studies

  摘要：

  1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K-i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a, MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

  DOI：

  10.1021/jm200363d

文献信息

• Pyrimidinone compounds
  申请人：SmithKline Beecham p.l.c.

  公开号：US20040167142A1

  公开（公告）日：2004-08-26

  Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA 2 and of use in therapy, in particular for treating atherosclerosis. 1

  式（I）的嘧啶酮化合物是Lp-PLA2酶的抑制剂，可用于治疗，特别是用于治疗动脉粥样硬化。
• Novel Processes for the manufacture of Propane-1-sulfonic acid -amide
  申请人：Brumsted Corey James

  公开号：US20120022258A1

  公开（公告）日：2012-01-26

  According to the present invention there are provided novel processes for the manufacture of the compound of formula 1 as well as intermediates and novel synthesis routes for key intermediates used in those processes.

  根据本发明提供了制备化合物1的新工艺，以及用于这些工艺中的中间体和关键中间体的新合成路线。
• [EN] 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE 7-PHÉNOXYCHROMANECARBOXYLIQUE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010075200A1

  公开（公告）日：2010-07-01

  Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.

  化合物的化学式I：（I），其中A，A1，R1，R7a，R7b，R8和R10具有规范中给定的含义，是DP2受体抑制剂，在治疗免疫性疾病、过敏性疾病（如哮喘、过敏性鼻炎和特应性皮炎）以及由前列腺素D2（PGD2）介导的其他炎症性疾病的治疗中有用。化合物的化学式I也可能在治疗涉及Th2 T细胞通过IL-4、IL-5和/或IL-13产生的疾病或医疗状况中有用。
• Strategy for Employing Unstabilized Nucleophiles in Palladium-Catalyzed Asymmetric Allylic Alkylations
  作者：Barry M. Trost、David A. Thaisrivongs

  DOI：10.1021/ja806781u

  日期：2008.10.29

  unstabilized anions in palladium-catalyzed asymmetric allylic alkylations (AAA). The "hard" 2-methylpyridyl nucleophiles studied are first reacted in situ with BF3.OEt2; subsequent deprotonation of the resulting complexes with LiHMDS affords "soft" anions that are competent nucleophiles in AAA reactions. The reaction is selective for the 2-position of methylpyridines and tolerates bulky aryl and alkyl substitution

  我们报告了在钯催化的不对称烯丙基烷基化 (AAA) 中使用高度不稳定的阴离子的策略。所研究的“硬”2-甲基吡啶基亲核试剂首先与 BF3.OEt2 原位反应；随后所得复合物与 LiHMDS 的去质子化提供“软”阴离子，在 AAA 反应中是有能力的亲核试剂。该反应对甲基吡啶的 2-位具有选择性，并且可以耐受 3-、4-和 5-位的大芳基和烷基取代。对反应机理的研究表明，保留了烯丙基立体中心的构型，这与为稳定阴离子的钯催化烯丙基取代过程所调用的规范外球机制一致。
• Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis
  申请人：Merck Frosst Canada, Inc.

  公开号：US05202321A1

  公开（公告）日：1993-04-13

  Compounds having the formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, psoriasis, uveitis and allograft rejection and in preventing the formation of atherosclerotic plaques.

  具有公式I的化合物：##STR1## 是白三烯生物合成的抑制剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑血管痉挛、肾小球肾炎、肝炎、内毒素血症、牛皮癣、葡萄膜炎和移植排斥，并预防动脉粥样硬化斑块的形成。